BACKGROUND: @entity1149 ( @entity1149 ) imposes a substantial burden on @entity1 , health care systems and society due to increasing incidence and poor survival rates. In recent years, advances in the treatment of metastatic @entity1149 have resulted from the introduction of targeted therapies. However, the application of these new agents increases treatment costs considerably. The objective of this article is to review the economic evidence of targeted therapies in metastatic @entity1149 . METHODS: A systematic literature review was conducted to identify cost-effectiveness (CE) as well as cost-utility studies. Medline, Embase, SciSearch, Cochrane, and 9 other databases were searched from 2000 through April 2013 (including update) for full-text publications. The quality of the studies was assessed via the validated Quality of Health Economic Studies (QHES) instrument. RESULTS: Nineteen studies (including update) involving the MoAb bevacizumab and the @entity669 -kinase inhibitors @entity3866 and @entity4562 met all inclusion criteria. The majority of studies analyzed the CE of first-line maintenance and second-line treatment with @entity3866 . Five studies dealt with bevacizumab in first-line regimes. @entity4562 and pharmacogenomic profiling were each covered by only two studies. Furthermore, the available evidence was of only fair quality. CONCLUSION: First-line maintenance treatment with @entity3866 compared to Best Supportive Care (BSC) can be considered cost-effective. In comparison to @entity1205 , @entity3866 is likely to be cost-effective in subsequent treatment regimens as well. The insights for bevacizumab are miscellaneous. There are findings that @entity4562 is cost-effective in first- and second-line treatment, however, based on only two studies. The role of pharmacogenomic testing needs to be evaluated. Therefore, future research should improve the available evidence and consider pharmacogenomic profiling as specified by the European Medicines Agency. Upcoming agents like @entity9816 and @entity12379 need to be analyzed as well.

A systematic review of the cost-effectiveness of targeted therapies for metastatic XXXX ( @entity1149 ).

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4562 :: ('MESH:C419708', 'Chemical') :: ['gefitinib', 'Gefitinib'] @entity12379 :: ('MESH:C522924', 'Chemical') :: ['afatinib'] @entity9816 :: ('MESH:C551994', 'Chemical') :: ['crizotinib'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'Non-small cell lung cancer'] @entity669 :: ('CHEBI:18186', 'Chemical') :: ['Tyrosine'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity3866 :: ('MESH:C400278', 'Chemical') :: ['erlotinib']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
